IGF-1 LR3

A Strong Rationale That Did Not Translate

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

The IGF-1 receptor was an attractive oncology target because IGF-1 signalling promotes proliferation and opposes cell death. Chen reviewed the programmes in 2013 under the title trials and tribulations, and Yee reviewed anti-IGF therapy in breast cancer in 2018.

Key facts

Target
IGF-1 receptor (IGF-1R)
Rationale
Proliferative and anti-apoptotic signalling
Chen 2013
Chin J Cancer (PMID 23601239)
Yee 2018
J Mol Endocrinol (PMID 29378771)
Outcome
Programmes largely unsuccessful
Complication
Insulin receptor similarity

Why the target looked so promising

IGF-1 receptor signalling drives proliferation and suppresses apoptosis, and elevated signalling had been associated with several cancers. Laron syndrome supplied the human genetic argument. Blocking the receptor should therefore remove a growth signal tumours were using. That is about as clean a rationale as oncology target selection produces.

What happened instead

Chen titled the 2013 review trials and tribulations, which conveys the outcome. Multiple agents entered clinical development and the programmes largely did not deliver the benefit the biology predicted. Yee's 2018 review of anti-IGF therapy in breast cancer covers the same territory in one disease.

Research material referenced

IGF-1 LR3 1mg, third-party HPLC tested

Buy IGF-1 LR3 · £49.99

The insulin receptor problem

The IGF-1 receptor and the insulin receptor are structurally close and can form hybrid receptors containing subunits of both. That creates two difficulties: achieving selectivity is hard, and blocking IGF-1R can disturb glucose handling. A target that cannot be engaged without touching insulin signalling has a narrow therapeutic window before anything else is considered.

Redundancy as the deeper problem

Tumours generally depend on more than one growth pathway. Removing one signal frequently produces compensation through another, which is why single-pathway inhibition so often disappoints in oncology. IGF-1R blockade appears to be a clear instance of that pattern rather than an exception to it.

Why the failure does not refute the biology

Laron syndrome concerns lifelong congenital absence of a signal. An antibody given to an adult with established disease is a different intervention entirely, with different timing, different completeness and a different starting point. A pathway can matter for whether cancer arises over decades while blocking it late changes little. Prevention and treatment are different problems.

What this contributes to reading any mechanism claim

That a strong biological rationale, supported by human genetics, is not sufficient. The distance between a mechanism being real and an intervention working is where most drug development fails, and this is one of the better-documented examples of that distance.

Frequently asked questions

Why was IGF-1R an oncology target?

Its signalling promotes proliferation and opposes apoptosis, and Laron syndrome supplied a human genetic argument that the axis matters in cancer.

What happened to those programmes?

They largely failed. Chen's 2013 review is titled 'trials and tribulations', which conveys the outcome accurately.

Does the failure disprove the biology?

No. Lifelong congenital absence and late blockade in established disease are different interventions. Prevention and treatment are different problems.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More IGF-1 LR3 articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.